InfuSystem Holdings INFU 深 沪
等待开盘 10-20 09:30:00 美东时间
9.00
-0.290
-3.12%
华盛通- 最 高9.3482
- 今 开9.19
- 成交量 14.14万股
- 最 低 8.98
- 昨 收 9.29
- 总市值 1.84亿
- 52周最高 11.04
- 市盈率 静 83.33
- 换手率 0.69%
- 52周最低 4.61
- 委 比 23.97%
- 总股本 2042.60万
- 历史最高 23.26
- 量 比 0.87
- 振 幅 3.96%
- 历史最低 0.75
- 每 手 1
- 风险率 1.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InfuSystem Holdings Reports Strong 2024 Revenue Growth
An announcement from InfuSystem Holdings ( ($INFU) ) is now available. InfuSyst...
10-07 05:51
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Lake Street Assumes InfuSystems Holdings at Buy, Announces Price Target of $15
Lake Street analyst Benjamin Haynor assumes InfuSystems Holdings (AMEX:INFU) with a Buy rating and announces Price Target of $15.
09-22 22:02
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initi...
08-30 05:00
InfuSystem Updates Its Annual Guidance For The Full Year 2025 With Net Revenue Growth Estimated Of 6%-8%, Versus Prior Range Of 8%-10%
Full Year 2025 GuidanceInfuSystem is updating its annual guidance for the full year 2025 with net revenue growth estimated to be in the 6% to 8% range. The prior net revenue growth range was 8% to 10%. We are also
08-05 18:33
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Insights Ahead: InfuSystems Holdings's Quarterly Earnings
InfuSystems Holdings (AMEX:INFU) is set to give its latest quarterly earnings r...
08-05 05:04
InfuSystem Holdings to Announce Q2 2025 Results
The latest update is out from InfuSystem Holdings ( ($INFU) ). InfuSystem Holdi...
07-30 04:50
美股大行评级 | 丰业银行上调Meta目标价从525美元升至675美元；恩智浦获"超配"评级，目标价从190美元升至220美元
今日重点评级关注：瑞杰金融：维持Antero Resources Corp."强烈买入"评级，目标价从57美元升至58美元；美银证券：维持和黄医药"买入"评级，目标价从27美元升至28美元
07-23 09:42
Roth Capital Initiates Coverage On InfuSystems Holdings with Buy Rating, Announces Price Target of $12
Roth Capital analyst Kyle Bauser initiates coverage on InfuSystems Holdings (AMEX:INFU) with a Buy rating and announces Price Target of $12.
07-23 01:57
